{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:18Z","timestamp":1792012158543,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jaad.2023.10.034","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T19:15:14Z","timestamp":1697915714000},"page":"521-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study"],"prefix":"10.1016","volume":"90","author":[{"given":"Joslyn S.","family":"Kirby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen B.","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2023.10.034_bib1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2023.10.034_bib2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa?-15 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.034_bib3","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: a review","volume":"183","author":"Matusiak","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.034_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.034_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2021.12.062","article-title":"Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes","volume":"87","author":"Shao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.034_bib6","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jid.2018.04.001","article-title":"Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis","volume":"138","author":"Garg","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.034_bib7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.034_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.034_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/der2.110","article-title":"Biologics and small molecule inhibitors for hidradenitis suppurativa","volume":"3","author":"Shih","year":"2022","journal-title":"Dermatol Rev"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u201cwindow of opportunity\u201d in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.10.034_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.12788\/j.sder.2018.042","article-title":"Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa","volume":"37","author":"Porter","year":"2018","journal-title":"Semin Cutan Med Surg"},{"issue":"11","key":"10.1016\/j.jaad.2023.10.034_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.jaad.2023.10.034_bib16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","article-title":"Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis","volume":"69","author":"Rumberger","year":"2020","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaad.2023.10.034_bib17","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.034_bib18","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2023.10.034_bib19","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.10.034_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.034_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087185","article-title":"Modulation of disease-associated pathways in hidradenitis suppurativa by the Janus kinase 1 inhibitor povorcitinib: transcriptomic and proteomic analyses of two phase 2 studies","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jaad.2023.10.034_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14656566.2022.2070429","article-title":"Advances in biologic and small molecule therapies for hidradenitis suppurativa","volume":"23","author":"Chen","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.det.2015.08.004","article-title":"Inflammatory mechanisms in hidradenitis suppurativa","volume":"34","author":"Kelly","year":"2016","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2023.10.034_bib25","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.034_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.034_bib27","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.034_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.034_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.10.034_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/bjd\/ljac141","article-title":"Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial setting","volume":"188","author":"Santos","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.10.034_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1087-0024.2004.09113.x","article-title":"10 years experience of the Dermatology Life Quality Index (DLQI)","volume":"9","author":"Lewis","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.034_bib32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.15519","article-title":"Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on quality of life and patient-oriented outcomes and acne, rosacea and hidradenitis suppurativa","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2023.10.034_bib33","first-page":"1441","article-title":"Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT-F) questionnaire","volume":"19","author":"Cella","year":"2011","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2023.10.034_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjd.14464","article-title":"Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Kimball","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.10.034_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2023.10.034_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10378","key":"10.1016\/j.jaad.2023.10.034_bib37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223030372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223030372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:29:20Z","timestamp":1759274960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223030372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0190962223030372"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.10.034","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}